Zoetis Inc. (NYSE:ZTS) Shares Acquired by AGF Management Ltd.

AGF Management Ltd. boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 93.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,296 shares of the company's stock after buying an additional 42,547 shares during the quarter. AGF Management Ltd.'s holdings in Zoetis were worth $17,427,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ZTS. Whittier Trust Co. boosted its position in shares of Zoetis by 8.8% during the 3rd quarter. Whittier Trust Co. now owns 10,500 shares of the company's stock worth $1,827,000 after purchasing an additional 849 shares during the period. Assetmark Inc. boosted its position in Zoetis by 4.0% in the 3rd quarter. Assetmark Inc. now owns 55,040 shares of the company's stock valued at $9,576,000 after buying an additional 2,142 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in Zoetis by 11.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 5,115 shares of the company's stock valued at $890,000 after buying an additional 526 shares during the period. Perigon Wealth Management LLC lifted its position in shares of Zoetis by 1.7% during the 3rd quarter. Perigon Wealth Management LLC now owns 23,522 shares of the company's stock worth $4,092,000 after purchasing an additional 404 shares during the last quarter. Finally, Mcdonald Partners LLC raised its stake in Zoetis by 2.9% during the 3rd quarter. Mcdonald Partners LLC now owns 5,304 shares of the company's stock worth $923,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the sale, the executive vice president now owns 14,800 shares of the company's stock, valued at approximately $2,237,316. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is owned by insiders.

Zoetis Stock Up 0.5 %

NYSE ZTS traded up $0.91 during trading on Friday, reaching $169.04. The company's stock had a trading volume of 2,010,749 shares, compared to its average volume of 4,781,720. The business has a 50-day moving average price of $165.90 and a 200-day moving average price of $178.77. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock has a market capitalization of $77.13 billion, a PE ratio of 32.57, a PEG ratio of 2.61 and a beta of 0.86.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analysts' expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.31 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. Piper Sandler restated an "overweight" rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. The Goldman Sachs Group decreased their target price on shares of Zoetis from $223.00 to $196.00 and set a "buy" rating on the stock in a research report on Monday, May 6th. Stifel Nicolaus cut their price target on shares of Zoetis from $195.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, April 30th. Finally, HSBC cut their target price on shares of Zoetis from $230.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and a consensus price target of $211.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.